AU2018359924A1

AU2018359924A1 - Composition for eliminating striae distensae

Info

Publication number: AU2018359924A1
Application number: AU2018359924A
Authority: AU
Inventors: Huimin Luo; Jian Sun; Guozhu WANG
Original assignee: Shaanxi HuiKang Bio Tech Co Ltd
Current assignee: Shaanxi HuiKang Bio Tech Co Ltd
Priority date: 2017-11-03
Filing date: 2018-10-29
Publication date: 2020-05-28
Anticipated expiration: 2038-10-29
Also published as: WO2019085852A1; AU2018359924B2; AU2020100737A4; HK1252300A2; CN109745253A; CN109745253B

Abstract

A composition for eliminating striae distensae. The composition consists of an essential oil blend and a cream. The essential oil blend comprises a base oil, a lavender essential oil, a myrtle essential oil, a frankincense essential oil, a patchouli essential oil, a vetiver essential oil, a carrot seed essential oil, a palmarosa essential oil, a basil essential oil, and the like. The cream comprises a base cream and an essential oil composition. Multiple natural plant essential oils promoting blood circulation, stimulating collagen regeneration, firming the skin, reducing skin roughness, and reorganizing fiber tissue structures are blended with the base oil, and then combined with the cream comprising multiple skin-moisturizing and absorption-facilitating ingredients for use. These ingredients have a synergistic effect and are highly effective, such that active components quickly enter the skin and become absorbed, thereby eliminating striae distensae and moisturizing and smoothing the skin at the same time.

Description

COMPOSITION FOR REMOVING STRIAE ATROPHICAE

TECHNICAL FIELD

The present invention belongs to the technical field of skincare products, and more particularly, to a composition for removing striae atrophicae.

BACKGROUND

Plant essential oils, derived from aromatic Herbst containing balsam glands, are highlyconcentrated extracts of aromatic plants and extracted by means of distillation and pressing from aromatic materials such as flowers, leaves, roots, bark, fruits, seeds, resins and the like that are unique to the plants. Most plant essential oils contain alcohols, aldehydes, acids, phenols, acetones, and terpenes. In fact, they are composed of more than 100 components, while some are even composed of up to thousands of components. For example, 86% of rose essential oil is composed of more than 300 components, with 14% thereof consisted of many minor compounds. Essential oil may be easily absorbed by the human body because of its high volatility and small molecules, and can quickly penetrate into human organs while discharging any excess components out of the body. The whole process only takes a few minutes. The fragrance of the plant itself also directly stimulates the secretion of the pituitary gland and the secretion of enzymes and hormones, balancing the body and functioning in beautifying and nurturing the skin. The benefits of essential oils to the human body are unfathomable.

Striae atrophicae (a general term for striae gravidarum/striae distensae) is a phenomenon of skin fiber breaking occurred in the process of human growth and development, pregnancy or sudden weight gain, and striae atrophicae resulted from pregnancy is also called striae gravidarum. It is primarily formed under the influence of hormones. When the growth or expansion of local tissues leads to various degrees of damages or breaking of the elastic fibers and collagen fibers in the skin due to external pulling, the skin becomes thinner and finer, and there may appear some undulate stripes of a pink or purplish red color varying in width and length on the abdomen, buttocks or other positions. Over time, these stripes will gradually disappear, leaving glossy scar streak lines of a white or silver color, that is, striae atrophicae. Some patients with striae atrophicae often have flabby abdominal skin, or even orange peel

12220453_1 (GHMatters) P113315.AU like changes in the skin.

Most women will undergo pregnancy, and according to the survey, more than 75% of pregnant women will have striae gravidarum after giving birth. During pregnancy, there are vast changes in hormones in women, including estrogen, progesterone, oxytocin, prolactin, and corticosteroids and the like. Among them, corticosteroids which are secreted by the adrenal gland will lead to pigmentation of the abdominal skin and increase the fragility of elastic and collagen fibers in the skin when increased. As the fetus grows bigger, the abdomen gradually swells, and when the abdominal distention exceeds the bearing capacity ofthe abdominal skin, the skin elastic fibers and collagen fibers will break, thereby producing striae gravidarum. However, some women, under the influence of obesity, sudden weight gain or puberty hormones, may also have striae distensae which is similar to striae gravidarum without giving birth. Even some pathological factors, such as adrenocortical hypofunction, huge ovarian tumor resection, large amount of ascites regression and the like, may lead to similar skin marks.

Simple essential oil is a simple plant essential oil, generally 100% pure, and cannot be directly used on the skin. Normally, it is added to cosmetics and can only be used when compounded with a base oil. Compound essential oil is a mixture of more than two types of single essential oils and base oil in a certain ratio, which can be directly used in skin care. They complement each other to enhance the efficacy.

Compound essential oil is a product from raw materials of plant extracts, and is widely used in skincare products due to its natural and safe characteristics. However, because of the synergistic and antagonistic effects among various types of essential oils, products obtained by different formulations and combinations vary greatly in efficacy, while most are formulated for a single function such as promoting blood circulation or improving the skin (with the help of professional hands). Currently, most compound essential oil products for removing striae atrophicae can be used for whole body massage, and have a proportion of the essential oil stock of 2% to 5%, which is used for an extended period of time and lacks effectiveness. Cream is a base material that is often used as a raw material for combination with essential oils due

12220453_1 (GHMatters) P113315.AU to its high safety factor and lack of preservatives. However, most of the commercial creams for combinational use have a low safety factor, while the majority, though claimed to moisturize the skin and increase collagen, are used for an extended period of time and lacks effectiveness.

SUMMARY OF THE INVENTION

In order to overcome the disadvantages and deficiencies in the prior art and in application effects, an object of the present invention is to provide a composition which can effectively improve and be rapidly absorbed by the skin, improve the relaxation of the skin, moisturize the skin, and remove striae atrophicae.

A composition for removing striae atrophicae as used to solve the above technical problem is composed of a compound essential oil and a cream, wherein the compound essential oil is composed of the following raw materials in mass percentage:

base essential oil	89% to 95%
lavender essential oil	1% to 2%
Myrtus communis Linn essential oil	0.6% to 1.5%
frankincense essential oil	0.6% to 1.5%
Patchouli essential oil	0.5% to 1.1%
vetivertone essential oil	0.5% to 1.0%
carrot seed essential oil	0.5% to 1.0%
palmarosa essential oil	0.5% to 1.0%
basil essential oil	0.3% to 0.7%
C12-13 alkanol polyether-3	0.2% to 0.6%
water	0.1% to 0.3%
rosemary extract	0.1% to 0.3%
Argireline	0.0005% to 0.001%

The above compound essential oil is preferably composed of the following raw materials in mass percentage:

base essential oil

90% to 93%

12220453_1 (GHMatters) P113315.AU

lavender essential oil	1.5% to 2%
Myrtus communis Linn essential oil	0.8% to 1.3%
frankincense essential oil	0.8% to 1.2%
Patchouli essential oil	0.8% to 1.0%
vetivertone essential oil	0.8% to 1.0%
carrot seed essential oil	0.5% to 1.0%
palmarosa essential oil	0.5% to 1.0%
basil essential oil	0.4% to 0.5%
C12-13 alkanol polyether-3	0.2% to 0.5%
water	0.1% to 0.3%
rosemary extract	0.1% to 0.2%
Argireline	0.001%

The above base essential oil is a mixture of any one of rosehip oil, grape seed oil, and macadamia oil together with jojoba oil, preferably a mixture of any one of rosehip oil, grape seed oil, and macadamia oil together with jojoba oil at a mass ratio of 1:1-2.

The above cream is composed of the following raw materials in mass percentage:

base cream 98.5% to 99.5% essential oil composition

0.5% to 1.5%

The above cream is composed of the following raw materials in mass percentage:

1,3-butanediol	3.5% to 4.5%
caprylic/ capric triglycerides	3.5% to 4.5%
glycerol	2.5% to 3.5%
isononyl isononanoate	2.5% to 3.5%
dioctyl carbonate	2.5% to 3.5%
cetearyl glucoside	1.5% to 2.5%
betaine	1.5% to 2.5%
polydimethylsiloxane	1.5% to 2.5%

12220453_1 (GHMatters) P113315.AU

jojoba oil	1.5% to 2.5%
potassium cetyl phosphate	1.5% to 2.5%
ethylhexylglycerol	0.3% to 0.6%
hexamethylene glycol	0.3% to 0.6%
hydroxyacetophenone	0.3% to 0.6%
Carbomer	0.05% to 0.15%
triethanolamine	0.05% to 0.15%
Argireline	0.0005% to 0.0015%
water	add to 100%

The above essential oil composition is composed of the following raw materials in mass percentage:

lavender essential oil	15% to 35%
Myrtus communis Linn essential oil	10% to 20%
frankincense essential oil	10% to 15%
Patchouli essential oil	10% to 15%
vetivertone essential oil	8% to 15%
carrot essential oil	8% to 15%
palmarosa essential oil	8% to 15%
basil essential oil	2% to 5%

The above essential oil composition is preferably composed of the following raw materials in mass percentage:

lavender essential oil	20% to 30%
Myrtus communis Linn essential oil	12% to 19%
frankincense essential oil	12% to 15%
Patchouli essential oil	10% to 13%
vetivertone essential oil	10% to 12%
carrot essential oil	10% to 12%
palmarosa essential oil	10% to 12%

12220453_1 (GHMatters) P113315.AU basil essential oil 3% to 5%

The above compound essential oil is prepared as follows: adding lavender essential oil, Myrtus communis Linn essential oil, frankincense essential oil, Patchouli essential oil, vetivertone essential oil, carrot seed essential oil, palmarosa essential oil, basil essential oil, and rosemary extract in this order in the above-mentioned mass percentage to the base essential oil to obtain a mixed essential oil; dissolving Argireline in water evenly, adding the resultant to C12-13 alkanol polyether-3, stirring and mixing at room temperature, and then pouring into the mixed essential oil; stirring and mixing at room temperature, packing and sealing to obtain the compound essential oil.

The above cream is prepared as follows: adding water, 1,3-butanediol, glycerol, betaine, hexamethylene glycol, and Carbomer in the above-mentioned mass percentage into an emulsifying tank, heating under stirring to 85 °C for 20 minutes to obtain a water phase; adding caprylic/ capric triglycerides, isononyl isononanoate, dioctyl carbonate, cetearyl glucoside, polydimethylsiloxane, jojoba oil, and potassium cetyl phosphate into an oil phase tank, heating to 85 °C for 20 minutes to obtain an oil phase; mixing lavender essential oil, Myrtus communis Linn essential oil, frankincense essential oil, Patchouli essential oil, vetivertone essential oil, carrot seed essential oil, palmarosa essential oil, and basil essential oil evenly under stirring to obtain an essential oil composition; adding the oil phase into the emulsifying tank and stirring evenly, homogenizing for 2 minutes, cooling to 75 °C, adding triethanolamine, stirring for 15 minutes while maintaining the temperature, and then cooling down under stirring and vacuum pumping; adding hydroxyacetophenone at 50 °C, cooling to 40 °C, adding the essential oil composition, ethylhexylglycerol, and Argireline, followed by vacuum pumping and slow stirring to cool down, and canning and sealing to obtain the cream.

The composition for removing striae atrophicae of the invention is used as follows: wiping off water on the human skin site having striae atrophicae; applying the compound essential oil to the site with striae atrophicae and pressing gently until it is warmed and absorbed, or applying the oil to the site with striae atrophicae and covering the site with a fresh-keeping film until

12220453_1 (GHMatters) P113315.AU the oil is absorbed; and then applying the cream and pressing gently until it is absorbed, wherein the amount of the compound essential oil applied is 0.05-0.1 mg/ cm² and the amount of the cream applied is 0.1-0.5 mg/ cm².

The functions of each active component of the invention are as follows:

Lavender essential oil is extracted from the flower of lavender and contains linalyl acetate ether, geraniol, linalool, eucalyptol, D-borneol, limonene, 1-pinene, caryophyllene, butyrate, valerenic acid, coumarin, which can effectively tighten the skin, shrink pores, control water-oil balance, remove spots and whiten the skin, remove wrinkle and increase skin tenderness, and also promote the regeneration and recovery of damaged tissues.

Myrtus communis Linn essential oil is extracted from leaves and twigs and has eucalyptol as the major component, in addition to myrtenal, pinene, geraniol, linalool, and camphorene. It is a very mild essential oil with antibacterial and astringent properties, and is capable of purifying the clogged skin to remove protrusions, and also eliminating congestion, as well as improving dry tinea and exfoliation appearances.

Frankincense essential oil is extracted from frankincense resin and has components including 1-pinene, dipentene, phellandrene, camphene, verbenol and a variety of rosins. It has a sweet and pure woody aroma, with a hint of fruitiness, and can make people feel extremely relaxed and soothed. It has functions in bacteria resistance, promoting scarring, fading scars and wrinkles, enhancing cell activities, and calming the skin, and may condition dry, aged, and dark skin, restore skin elasticity, and shrink pores.

Patchouli essential oil is extracted from stems and leaves and has patchouli alcohol, patchoulene, and n-patchouli alcohol as main components, and a small amount of eugenol, cadinene, carvone and the like. It can promote skin regeneration, reduce occurrence of inflammation, shrink skin pores, tighten the skin, promote wound healing, and facilitate the improvement in skin loosening resulted from excessive diet.

12220453_1 (GHMatters) P113315.AU

Vetivertone essential oil is extracted from roots and has vetivone, vetiverol, vetivene, and dusonene as main components. It is capable of conditioning and tightening the skin, diminishing inflammation and sterilizing, revitalizing cells, improving damaged skins, and promoting the regeneration and recuperation of body cells.

Carrot seed essential oil is extracted from carrot seed and has pinene, camphene, sabinene, laurene, dipentene or terpinene, limonene, bisabolene, geranyl acetate, and carotol as main chemical components. It can stimulate and rejuvenate the skin, increase skin elasticity, and has an apparent effect on eliminating wrinkles in the outer skin.

Palmarosa essential oil is extracted from palmarosa and has citral (about 75% to 95%) as its main component and a trace amount of citronellol, geranyl acetate, farnesol, etc. It can balance sebum secretion, reform the natural water-retaining film on the skin surface, showing an excellent moisturizing effect, and is effective in promoting the regeneration of epidermal cells, and bacteria and virus resistance and sterilization.

Basil essential oil is extracted from leaves and flowers. Basil is known as the king of herbs and very nourishing to women. It has an anti-aging effect, and can tighten and nourish the skin and improve loosen and aged skins.

Argireline, also known as Areginine Essence, has an active hexapeptide and may effectively relax and suppress forehead wrinkles as well as the contraction and movement of the peripheral muscles, facilitate muscle relaxation, and allows the skin elastic tissue to regain its soft and smooth profile. It has a function analogous to that of suppressing nerve conduction substances and blocking the conduction between nerves and muscles, avoiding excessive contraction of muscles, thereby preventing the formation of fine lines, reducing the occurrence of dynamic wrinkles, restoring the elasticity of tissue collagen, and making the skin smooth and tight.

In the present invention, a variety of natural plant essential oils which can promote blood

12220453_1 (GHMatters) P113315.AU circulation, stimulate collagen regeneration, tighten the skin, improve skin roughness, and reconstruct fiber tissue structure are scientifically formulated and function synergistically in removing striae atrophicae; when used in combination with a cream containing essential oil components, they demonstrate a synergistic effect and strong efficacy in mutual complementation, allowing active ingredients to quickly penetrate the skin to be absorbed, removing or reducing striae atrophicae, promoting cell regeneration, and improving skin dryness and loosening, which greatly improves striae atrophicae and achieves an effect of removing striae atrophicae while moisturizing and smoothing the skin, and is easy to use.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a photograph of the abdominal striae gravidarum of Ms. Wu before trial.

Figure 2 is a photograph of the abdominal striae gravidarum of Ms. Wu on day 20 after using the composition for removing striae atrophicae according to Example 1.

Figure 3 is a photograph of the abdominal striae gravidarum of Ms. Wu on day 40 after using the composition for removing striae atrophicae according to Example 1.

Figure 4 is a photograph of the back growth striae of Ms. Lei before trial.

Figure 5 is a photograph of the back growth striae of Ms. Lei on day 15 after using the composition for removing striae atrophicae according to Example 1.

Figure 6 is a photograph of the right abdominal striae gravidarum of Ms. WU before trial.

Figure 7 is a photograph of the right abdominal striae gravidarum of Ms. WU on day 60 after using the composition for removing striae atrophicae according to Example 1.

Figure 8 is a photograph of the left abdominal striae gravidarum of Ms. Li before trial.

Figure 9 is a photograph of the left abdominal striae gravidarum of Ms. Li on day 60 after using the composition for removing striae atrophicae according to Example 1.

Figure 10 is a photograph of the abdominal striae gravidarum of Ms. Liu before trial.

Figure 11 is a photograph of the abdominal striae gravidarum of Ms. Liu on day 15 after using the composition for removing striae atrophicae according to Example 1.

Figure 12 is a photograph of the abdominal striae gravidarum of Ms. Zhao before trial.

Figure 13 is a photograph of the abdominal striae gravidarum of Ms. Zhao on day 11 after using the composition for removing striae atrophicae according to Example 1.

12220453_1 (GHMatters) P113315.AU

Figure 14 is a photograph of the leg growth striae of Ms. Jiang before trial.

Figure 15 is a photograph of the leg growth striae of Ms. Jiang on day 24 after using the composition for removing striae atrophicae according to Example 1.

Figure 16 is a photograph of the back growth striae of Ms. Qin before trial.

Figure 17 is a photograph of the back growth striae of Ms. Qin on day 38 after using the composition for removing striae atrophicae according to Example 1.

Figure 18 is a photograph of the abdominal striae gravidarum of Ms. Feng before trial.

Figure 19 is a photograph ofthe abdominal striae gravidarum of Ms. Feng on day 10 after using the composition for removing striae atrophicae according to Example 1.

Figure 20 is a photograph ofthe abdominal striae gravidarum of Ms. Feng on day 15 after using the composition for removing striae atrophicae according to Example 1.

Figure 21 is a photograph of the abdominal striae gravidarum of Ms. Li before trial.

Figure 22 is a photograph ofthe abdominal striae gravidarum of Ms. Li on day 15 after using the composition for removing striae atrophicae according to Example 1.

Figure 23 is a photograph ofthe abdominal striae gravidarum of Ms. Li on day 45 after using the composition for removing striae atrophicae according to Example 1.

Figure 24 is a photograph of the leg growth striae of Ms. Han before trial.

Figure 25 is a photograph of the leg growth striae of Ms. Han on day 60 after using the composition for removing striae atrophicae according to Example 1.

Figure 26 is a photograph of the leg growth striae of Ms. Cui before trial.

Figure 27 is a photograph of the leg growth striae of Ms. Cui on day 45 after using the composition for removing striae atrophicae according to Example 1.

Figure 28 is a photograph of the abdominal striae gravidarum of Ms. Deng before trial.

Figure 29 is a photograph of the abdominal striae gravidarum of Ms. Deng on day 60 after using the composition for removing striae atrophicae according to Example 1.

Figure 30 is a photograph of the abdominal striae gravidarum of Ms. Shi before trial.

Figure 31 is a photograph of the abdominal striae gravidarum of Ms. Shi on day 60 after using the composition for removing striae atrophicae according to Example 1.

Figure 32 is a diagram of clinical ratings of striae atrophicae area, quantity, and color at weeks 0, 2, 4, 6 and 8.

12220453_1 (GHMatters) P113315.AU

Figure 33 is a histogram of changes in clinical rating of striae atrophicae area at weeks 0, 2,

4, 6 and 8.

Figure 34 is a histogram of changes in clinical rating of striae atrophicae color at weeks 0, 2, 4, 6 and 8.

Figure 35 is a histogram of changes in clinical grade of striae atrophicae quantity at weeks 0, 2, 4, 6 and 8.

Figure 36 is a curve of changes in average striae atrophicae surface area at weeks 0, 2, 4, 6 and 8.

Figure 37 to 41 respectively show the condition of five users A-E before using the product (left panel) and 8 weeks after using the product (right panel).

DETAILED DESCRIPTION OF THE INVENTION

The present invention will be further described in details in combination with the drawings and the Examples, but the protection scope of the invention is not limited to these Examples.

Example 1

The composition for removing striae atrophicae according to this Example is composed of a compound essential oil and a cream. In the case of preparing 100 g of the compound essential oil, it has a composition by mass of:

rosehip oil	46.0 g
jojoba oil	46.0 g
lavender essential oil	1.5 g
Myrtus communis Linn essential oil	1.2 g
frankincense essential oil	1.0 g
Patchouli essential oil	1.0 g
vetivertone essential oil	0.8 g
carrot seed essential oil	0.8 g
palmarosa essential oil	0.5 g
basil essential oil	0.5 g
C12-13 alkanol polyether-3	0.499 g

12220453_1 (GHMatters) P113315.AU

water	0.1 g
rosemary extract	0.1 g
Argireline	0.001 g
In the case of preparing 100 g of the cream,	it has a composition by mass of:
5 base cream	99 g
essential oil composition	ig
In the above cream, the base cream has a composition by mass percentage of:
1,3-butanediol	4%
caprylic/ capric triglycerides	4%
10 glycerol	3%
isononyl isononanoate	3%
dioctyl carbonate	3%
cetearyl glucoside	2%
betaine	2%
15 polydimethylsiloxane	1.5%
jojoba oil	1.5%
potassium cetyl phosphate	1.5%
ethylhexylglycerol	0.5%
hexamethylene glycol	0.5%
20 hydroxyacetophenone	0.5%
Carbomer	0.1%
triethanolamine	0.1%
Argireline	0.001%
water	add to 100%
25 In the above cream, the essential oil composition has a composition by mass percentage of:
lavender essential oil	25%
Myrtus communis Linn essential oil	15%
frankincense essential oil	13%
Patchouli essential oil	12%
30 vetivertone essential oil	10%

12220453_1 (GHMatters) P113315.AU carrot essential oil palmarosa essential oil basil essential oil

10%

5%

The above compound essential oil is prepared as follows: adding lavender essential oil, Myrtus communis Linn essential oil, frankincense essential oil, Patchouli essential oil, vetivertone essential oil, carrot seed essential oil, palmarosa essential oil, basil essential oil, and rosemary extract in this order in the above-mentioned mass percentage to the base essential oil to obtain a mixed essential oil; dissolving Argireline in water evenly, adding the resultant to C1213 alkanol polyether-3, stirring and mixing at room temperature, and then pouring into the mixed essential oil; stirring and mixing at room temperature, packing and sealing to obtain the compound essential oil.

Example 2

12220453_1 (GHMatters) P113315.AU

grape seed oil	44.5 g
jojoba oil	44.5 g
lavender essential oil	2.0 g
Myrtus communis Linn essential oil	1.5 g
frankincense essential oil	1.5 g
Patchouli essential oil	1.1 g
vetivertone essential oil	1.0 g
carrot seed essential oil	1.0 g
palmarosa essential oil	1.0 g
basil essential oil	0.7 g
C12-13 alkanol polyether-3	0.599 g
water	0.3 g
rosemary extract	0.3 g
Argireline	0.001 g

In the case of preparing 100 g of the cream, it has a composition by mass of:

base cream	99 g
essential oil composition	ig

In the above cream, the base cream has a composition by mass percentage of:

1,3-butanediol	4.5%
caprylic/ capric triglycerides	3.5%
glycerol	3.5%
isononyl isononanoate	2.5%
dioctyl carbonate	3.5%
cetearyl glucoside	1.5%
betaine	2.5%
polydimethylsiloxane	2.0%
jojoba oil	2.0%
potassium cetyl phosphate	2.0%
ethylhexylglycerol	0.3%
hexamethylene glycol	0.6%

12220453_1 (GHMatters) P113315.AU

Hydroxyacetophenone	0.3%
Carbomer	0.05%
triethanolamine	0.15%
Argireline	0.0005%
water	add to 100%

In the above cream, the essential oil composition has a composition by mass percentage of:

lavender essential oil	15%
Myrtus communis Linn essential oil	20%
frankincense essential oil	10%
Patchouli essential oil	15%
vetivertone essential oil	10%
carrot essential oil	15%
palmarosa essential oil	12%
basil essential oil	3%

The preparation methods of the above compound essential oil and cream are the same as those of Example 1.

Example 3

grape seed oil	31g
jojoba oil	62 g
lavender essential oil	1.0 g
Myrtus communis Linn essential oil	1.3 g
frankincense essential oil	1.2 g
Patchouli essential oil	0.8 g
vetivertone essential oil	0.5995 g
carrot seed essential oil	0.6 g
palmarosa essential oil	0.6 g

12220453_1 (GHMatters) P113315.AU

basil essential oil	0.3 g
C12-13 alkanol polyether-3	0.2 g
water	0.2 g
rosemary extracts	0.2 g
Argireline	0.0005 g

In the case of preparing 100 g of the cream, it has a composition by mass of:

base cream	99 g
essential oil composition	lg

In the above cream, the base cream has a composition by mass percentage of:

1,3-butanediol	3.5%
caprylic/ capric triglycerides	4.5%
glycerol	2.5%
isononyl isononanoate	3.5%
dioctyl carbonate	2.5%
cetearyl glucoside	2.5%
betaine	1.5%
polydimethylsiloxane	2.5%
jojoba oil	2.5%
potassium cetyl phosphate	2.5%
ethylhexylglycerol	0.6%
hexamethylene glycol	0.3%
Hydroxyacetophenone	0.6%
Carbomer	0.15%
triethanolamine	0.05%
Argireline	0.0015%
water	add to 100%

lavender essential oil	35%
Myrtus communis Linn essential oil	12%
frankincense essential oil	10%

12220453_1 (GHMatters) P113315.AU

Patchouli essential oil vetivertone essential oil carrot essential oil palmarosa essential oil basil essential oil

13%

8%

12%

8%

2%

Example 4

The composition for removing striae atrophicae according to this Example is composed of a compound essential oil and a cream. In the case of preparing 100 g of the compound essential oil, it has a composition by mass of: macadamia oil 47.5 g jojoba oil 47.5 g lavender essential oil1.0 g

Myrtus communis Linn essential oil0.6 g frankincense essential oil 0.699 g

Patchouli essential oil0.5 g vetivertone essential oil0.5 g carrot seed essential oil0.5 g palmarosa essential oil 0.5g basil essential oil0.3 g

C12-13 alkanol polyether-30.2 g water 0.1g rosemary extracts 0.1g

Argireline 0.001g

In the case of preparing 100 g of the cream, it has a composition by mass of: base cream99 g essential oil compositionlg

The above base cream has the same composition by mass percentage as that in Example 1,

12220453_1 (GHMatters) P113315.AU and the essential oil composition has a composition by mass percentage of:

lavender essential oil

Myrtus communis Linn essential oil frankincense essential oil

30%

10%

15%

8%

15%

2%

Example 5

The composition for removing striae atrophicae according to this Example is composed of a compound essential oil and a cream. In the case of preparing 100 g of the compound essential oil, it has a composition by mass of: rosehip oil 46.85 g jojoba oil 46.85g lavender essential oil1.5 g

Myrtus communis Linn essential oil1.0 g frankincense essential oil0.6 g

Patchouli essential oil0.5 g vetivertone essential oil0.5 g carrot seed essential oil0.5 g palmarosa essential oil0.5 g basil essential oil0.4 g

C12-13 alkanol polyether-3 0.399g water0.2 g rosemary extract0.2 g

Argireline 0.001g

12220453_1 (GHMatters) P113315.AU

The cream has the same composition as that in Example 1. The preparation methods of the above compound essential oil and cream are the same as those of Example 1.

Example 6

The composition for removing striae atrophicae according to the this Example is composed of a compound essential oil and a cream, wherein the compound essential oil has the same composition as that in Example 1. In the case of preparing 100 g of the cream, it has a composition by mass of:

base cream 99.5 g essential oil composition 0.5 g

The above base cream and essential oil composition has the same composition by mass percentage as that in Example 1. The preparation methods of the above compound essential oil and cream are the same as those of Example 1.

Example 7

The composition for removing striae atrophicae according to the this Example is composed of a compound essential oil and a cream, wherein the compound essential oil has the same composition as that in Example 5 and the cream has the same composition as that in Example 6. The preparation methods of the above compound essential oil and cream are the same as those of Example 1.

Example 8

base cream 99 g essential oil composition 1 g

In the above cream, the base cream has the same composition by mass percentage as that in Example 1, and the essential oil composition has a composition by mass percentage of:

12220453_1 (GHMatters) P113315.AU

lavender essential oil	20%
Myrtus communis Linn essential oil	17%
frankincense essential oil	15%
Patchouli essential oil	12%
vetivertone essential oil	12%
carrot essential oil	10%
palmarosa essential oil	10%
basil essential oil	4%

Example 9

The composition for removing striae atrophicae according to the this Example is composed of a compound essential oil and a cream, wherein the compound essential oil has the same composition as that in Example 5. In the case of preparing 100 g of the cream, it has a composition by mass of:

base cream 99 g essential oil composition 1 g

In the above cream, the base cream has the same composition by mass percentage as that in Example 1, and the essential oil composition has the same composition by mass percentage as that in Example 8.

Example 10

base cream

98.5 g

12220453_1 (GHMatters) P113315.AU essential oil composition 1.5 g

Example 11

The composition for removing striae atrophicae according to the this Example is composed of a compound essential oil and a cream, wherein the compound essential oil has the same composition as that in Example 5 and the cream has the same composition by mas percentage as that in Example 10.

In orderto demonstrate the beneficial effects of the present invention, the inventor has carried out extensive researches by using the composition for removing striae atrophicae according to Example 1. The test conditions in details are provided as follows.

I. Toxicological test

The toxicological test was carried on the cream in the composition for removing striae atrophicae according to Example 2, in accordance with the Cosmetic Safety Technical Specification (2015 Edition). The details were as follows:

1. Materials and methods (1) Test materials

Preparation of test solution: stock solution

Dosage: 0.5 ml per animal (2) Animal and feeding conditions

Animal: 4 New Zealand rabbits of common grade, weighing 2.1 kg to 2.7 kg, both male and female, were provided by Xi'an Dilepu Biological Resource Development Co., Ltd. Laboratory

12220453_1 (GHMatters) P113315.AU animal production license No.: SCXK (Shan) 2014-001. Feeding conditions: temperature: 22 °C to 26 °C, relative humidity: 40% to 70%, single-cage feeding, free access to water. Laboratory animal use license No.: SYXK (Shan) 2013-001. Animal-related information is shown in Table 1.

Table 1

Animal No.	1	2	3	4
Sex	female	female	male	male
Weight (KG)	2.5	2.7	2.4	2.1

Feed: complete pellet feed for rabbit, provided by Xi'an Dilepu Biological Resource

Development Co., Ltd. Feed production license No. SCXK (Shan) 2014-004.

(3) Test method:

Four quarantined adults healthy rabbits with no skin injury were selected. Hair on both sides of the spine of the rabbits was cut off one day before the test. Hair removal areas were about 3 cm x 3 cm each, and the skin was smooth and intact. During the test, 0.5 ml of the test solution was applied to the skin on the left side in an application area of 2.5 cm x 2.5 cm, with the skin on the right side left untreated as control: application once per day for consecutive 14 days. Starting on Day 2, hair was cut off and the residual test material was removed by using warm water before each application. One hour later, skin rating was performed, with the skin irritation response scored and skin irritation intensity determined according to relevant regulations of skin irritation/corrosion test in the Cosmetic Safety Technical Specification (2015 Edition).

2. Test results

During the test, no skin irritation such as erythema and edema on the skin of rabbits in the test area, and the average score in skin irritation response of each rabbit was 0.0, which was determined as no irritation according to relevant regulations of skin irritation/ corrosion test in the Cosmetic Safety Technical Specification (2015 Edition).

The test results are shown in Table 2.

Table 2. Results of multiple tests on skin irritation by cream in rabbit

Days of	Number of	Scores in skin irritation response
application	animals	Test substance	Control

12220453_1 (GHMatters) P113315.AU

		Erythema	Edema	Overall score	Erythema	Edema	Overall score
1	4	0	0	0	0	0	0
2	4	0	0	0	0	0	0
3	4	0	0	0	0	0	0
4	4	0	0	0	0	0	0
5	4	0	0	0	0	0	0
6	4	0	0	0	0	0	0
7	4	0	0	0	0	0	0
8	4	0	0	0	0	0	0
9	4	0	0	0	0	0	0
10	4	0	0	0	0	0	0
11	4	0	0	0	0	0	0
12	4	0	0	0	0	0	0
13	4	0	0	0	0	0	0
14	4	0	0	0	0	0	0
Average score per animal per day	0.0	0.0	0.0	0.0	0.0	0.0
Skin irritation response intensity	No irritation

3. Test conclusion: the cream in the composition for removing striae atrophicae according to

Example 2 has no irritation to the skin of rabbits in multiple irritation tests.

II. Toxicological test

The toxicological test was carried on the compound essential oil in the composition for removing striae atrophicae according to Example 2, in accordance with the Cosmetic Safety Technical Specification (2015 Edition). The details were as follows:

1. Materials and methods (1) Test materials

Preparation of test solution: stock solution

12220453_1 (GHMatters) P113315.AU

Dosage: 0.5 ml per animal (2) Animal and feeding conditions

Animal: 4 New Zealand rabbits of common grade, weighing 2.2 kg to 2.8 kg, both male and female, were provided by Xi'an Dilepu Biological Resource Development Co., Ltd. Laboratory animal production license No.: SCXK (Shan) 2014-001. Feeding conditions: temperature: 22 °C to 26 °C, relative humidity: 40% to 70%, single-cage feeding, free access to water. Laboratory animal use license No.: SYXK (Shan) 2013-001. Animal-related information is shown in Table 3. Table 3

Animal No.	1	2	3	4
Sex	female	female	male	male
Weight (KG)	2.3	2.2	2.6	2.8

Development Co., Ltd. Feed production license No. SCXK (Shan) 2014-004.

(3) Test method:

2. Test results

The test results are shown in Table 4.

12220453_1 (GHMatters) P113315.AU

Table 4. Results of multiple tests on skin irritation by compound essential oil in rabbit

Days of application	Number of animals	Scores in skin irritation response
Test substance	Control
Erythema	Edema	Overall score	Erythema	Edema	Overall score
1	4	1	0	1	0	0	0
2	4	1	0	1	0	0	0
3	4	1	0	1	0	0	0
4	4	1	0	1	0	0	0
5	4	1	0	1	0	0	0
6	4	0	0	0	0	0	0
7	4	0	0	0	0	0	0
8	4	0	0	0	0	0	0
9	4	0	0	0	0	0	0
10	4	0	0	0	0	0	0
11	4	0	0	0	0	0	0
12	4	0	0	0	0	0	0
13	4	0	0	0	0	0	0
14	4	0	0	0	0	0	0
Average score per animal per day	0.09	0.0	0.09	0.0	0.0	0.0
Skin irritation response intensity	No irritation

III. Cutaneous hypersensitivity test

Experimental animals: 30 white guinea pigs, half male and half female, weighing 260 to 300 g, were selected. Hairs on both sides ofthe spine of these animals were cut off with an electronic razor 24 hours before the test. Hair removal area on each side was 3x3 cm².

12220453_1 (GHMatters) P113315.AU

Animal grouping: the guinea pigs were randomly divided into three groups according to sex and weight, 10 in each group, as the test group, the positive control group, and the negative control group, respectively.

Test group: a 1 cm² square gauze was taken and dipped in the compound essential oil for 5 minutes, and then used as a patch and fixed in a semi-closed manner in the area where hair was removed on the back of the animals for 6 hours; the patch was then removed, and the cream was applied in an amount of the cream applied of 0.5 g/cm².

Positive control group: a 1 cm² square gauze was taken and dipped in an 0.1% (mass%) aqueous formaldehyde solution for 5 minutes, and then used as a patch and fixed in a semi-closed manner in the area where hair was removed on the back of the animals for 6 hours; the patch was then removed.

Negative control group: a 1 cm² square gauze was taken and dipped in normal saline for 5 minutes, and then used as a patch and fixed in a semi-closed manner in the area where hair was removed on the back of the animals for 6 hours; the patch was then removed.

Occurrence of phenomenons such as erythema and edema on the skin at the stimulated site in each group of animals was observed and recorded once a day for 6 consecutive days, then scored according to the criteria, and the sensitization rate was calculated.

Determination and evaluation of the results: the test results are represented in skin reaction intensity and sensitization positive rate of the animals. The skin reaction intensity is scored based on the following two criteria:

(1) light erythema (barely visible) is scored 1; light erythema with clear boundary is 2; moderate erythema (bright red to deep red) is 3; severe erythema (deep red to purplish red, with eschar formation) is 4.

(2) very slight edema (hardly noticeable) is scored 1; slight edema (with an edge obviously higherthan the skin surface) is 2; moderate edema (with a swelling of about 1 mm higherthan the skin surface) is 3; severe edema (with a swelling of more than 1 mm higher than the skin surface and having an area exceeding the patch area) is 4.

The overall score is the sum of the erythema score and the edema score, and it was successively determined whether the animal had an allergic reaction. The sensitization positive rate is a percentage of the ratio between the number of positive animals and the total

12220453_1 (GHMatters) P113315.AU number of animals. The sensitization intensity of the chemicals was rated on the basis of this percentage. Sensitization intensity ratings are shown in Table 5, and the test results are shown in Table 6.

Table 5. Sensitization intensity ratings

Sensitization rate (%)	Rating	Sensitization intensity
0-8	1	slight sensitization
9-28	II	light sensitization
28-64	III	moderate sensitization
64-80	IV	strong sensitization
81-100	V	very strong sensitization

Table 6. Sensitization test results

Groups

No. of Animals

Reaction types

Observation time and reaction intensity scores

Group overall scores

Average reaction scores

Sensitization rate

Sensitization intensity

Id

2d

3d

4d

5d

6d

Positive control group

10

Erythema

1/1

1/3

2/2

3/4

42

0.8

100%

moderate sensitization

Edema

1/2

1/4

3/4

3/5

57

1.1

Test group

10

Erythema

0/0

0

none

Edema

0/0

0

none

Negative control group

10

Erythema

0/0

0

none

Edema

0/0

0

none

Note: in this table, 1/ 3 = rated 1/3 anima s, i.e., 3 animals were rated 3.

As seen from table 6, no animal having a sensitization reaction is present in the test group, indicating that the compound essential oil and the cream in the composition for removing striae atrophicae of the present invention is not sensitizing.

IV. Irritation test people were randomly selected and applied with the compound essential oil or cream of Example 1 on the inner side of their arms until absorption. After 30 seconds, those applied with the compound essential oil of Example 1 shows a slight warm feeling and no discomfort,

12220453_1 (GHMatters) P113315.AU and those applied with the cream of Example 1 shows no warm feeling or discomfort.

V. Efficacy test volunteers were randomly selected for the trial of the composition for removing striae atrophicae of Example 1. The 30 volunteers, aged 25 to 50 years old, had conditions of striae atrophicae at different sites to a certain extent. The trial was specifically carried out as follows: the human skin site with striae atrophicae was cleaned and dried, applied with the compound essential oil and pressed gently until it was absorbed, and then applied with the cream and pressed gently until it was absorbed, with an application amount ofthe compound essential oil of 0.07 mg/ cm² and an application amount of the cream of 0.3 mg/ cm². The trial went on for 6 months, and the results were indicated by an efficacy of the percentage of the number of volunteers achieving the target effect to the total number of volunteers with problems. The results of the trial were as follows:

month after trial: striae distensae at any body sites, whether obesity striae resulted from obesity or striae gravidarum due to pregnancy, was lightened. The results showed an significant improvement in skin firmness and reduction of striae atrophicae in all 30 people, with an effective rate of 100%; 15 out of the 30 volunteers had striae gravidarum in their abdomen and legs due to pregnancy, and the results showed that 14 had the striae gravidarum lightened and the skin appeared smooth and bright, with an effective rate of 93.33%; 15 out of the 30 volunteers had striae due to obesity or other reasons, and the results showed that 14 had the striae lightened and the skin appeared firm and delicate, with an effective rate of 93.33%; in terms of improvement in fullness, brightness, and tightness ofthe skin, the effective rate was 100%; above all, the overall effective rate of removing striae atrophicae after one month of trial was 93.33%.

months after trial: in the 15 people having striae gravidarum due to pregnancy among the 30 volunteers, 13 showed disappearance of 90% of the striae gravidarum at their body sites and the skin appeared tender and tight, with an effective rate of 86.67%; for those having striae atrophicae due to obesity and other factors, 13 showed complete disappearance, 1 had 90% striae disappeared, and the skin appeared tender and tight, with an effective rate of 93.33%. Above all, the overall effective rate was 90%.

12220453_1 (GHMatters) P113315.AU months after trial: in the 15 people having striae gravidarum due to pregnancy among the volunteers, 14 showed complete disappearance of the striae gravidarum at their body sites and the skin appearred tender and tight, with an effective rate of 93.33%; for the 15 volunteers having striae atrophicae due to obesity and other factors, the striae atrophicae completely disappeared, with an effective rate of 100%. Above all, the overall effective rate was 96.65%.

VI. Typical cases

Ms. Wu, age 33, employee, had striae gravidarum for 3 years, with obvious striae gravidarum in the right abdomen with clear streaks and a fair area (shown in Figure 1). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 20 consecutive days, and the streaks were significantly shortened with some already faded (see Figure 2); after applied for 40 consecutive days, the previous striae gravidarum became scattered dots, showing obvious fading and recovery (see Figure 3).

Ms. Lei, age 28, employee, had apparent growth striae on the back in long streaks with tight gaps (shown in Figure 4). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 15 consecutive days, and the long streaks on the back were substantially flattened, with the undulate streaks almost disappeared (shown in Figure 5).

Ms. WU, age 33, employee, had striae gravidarum for 2 years, with apparent discontinuous streaks in dark colors in the right abdomen together with depressed areas (shown in Figure 6). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 60 consecutive days, and the discontinuous streaks substantially disappeared, showing a normal skin state (shown in Figure 7).

Ms. Li, age 35, had striae gravidarum for one and a half years, with layered streaks present on the left side of the abdomen that have an obvious streak feeling when touched by hand (shown in Figure 8). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 60 consecutive days, and the side streaks already disappeared, and there was no obvious streak but a delicate

12220453_1 (GHMatters) P113315.AU and soft feeling when touched by hand (shown in Figure 9).

Ms. Liu, age 30, employee, had striae gravidarum in abdomen for 3 years, with undulate orange peel-like streaks in a large area, showing a disordered pattern and dry and rough skin (shown in Figure 10). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 15 consecutive days, and the orange peel-like appearance and the roughness and dryness of the skin were significantly improved, with the skin streaks narrowed and shortened (shown in Figure 11).

Ms. Zhao, age 35, had striae gravidarum for 4 years, with apparent abdominal pigmentation circles and mesh-like streaks in a large area (shown in Figure 12). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 11 consecutive days, and the pigmentation circles bacame significantly smaller with the color lightened, and the streaks on the lower abdomen and on the side were significantly reduced (shown in Figure 13).

Ms. Jiang, age 30, had striae gravidarum for 4 years, with long and root-like streaks on the leg (shown in Figure 14). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 24 consecutive days, and the streaks on the leg were obviously significantly shortened and reduced (shown in Figure 15).

Ms. Qin, age 28, employee, had growth striae for 1 year, with long and deep growth striae on the back (shown in Figure 16). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 38 consecutive days, and the growth striae on the back became shorter in length and smaller in depth (shown in Figure 17).

Ms. Feng, age 31, employee, had striae gravidarum for 2 years, with obvious discontinuation of the skin on the side of the abdomen, together with clear purplish red marks at the discontinuation (shown in Figure 18). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 10 consecutive days, and the purplish marks faded in color (shown in Figure 19); after applied for 15 consecutive days, the skin texture color returned to normal, and the streaks essentially dissappeared (shown in Figure 20).

12220453_1 (GHMatters) P113315.AU

Ms. Li, age 32, employee, had striae gravidarum for 2 years, with apparent discontinuation of the skin layer on both two sides (see Figure 21) together with clear pigmentation at the discontinuation (more severe on the right side). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 30 consecutive days, and both the streaks and the pigmentation became significantly faded (see Figure 22); after applied for 45 consecutive days, streaks on both sides essentially faded, showing a restoration of the discontinuation layer (slight discontinuation still present on the right side), as shown in Figure 23.

Ms. Han, age 27, employee, had growth striae for 2 years, with apparent, wide and layered growth streaks on the leg (see Figure 24). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 60 consecutive days, and some of the white streaks on the leg were narrowed, with some disappeared (see Figure 25).

Ms. Cui, age 23, student, had growth striae for 5 years, with appearance of apparent streaks on the inner side of the legs (see Figure 26). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 45 consecutive days, and some of streaks disappeared, with some significantly shortened (see Figure 27).

Ms. Deng, age 35, employee, had striae gravidarum for 6 years, with many prominent streaks in the abdomen in an obviously large area and pigmentation (see Figure 28). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 60 consecutive days, and the prominent streaks were shortened and the pigmentation was lightened (see Figure 29).

Ms. Shi, age 36, employee, had striae gravidarum for 4 years, with prominent abdominal streaks, together with serious pigmentation (see Figure 30). According to the method in the above test 3, the composition for removing striae atrophicae of Example 1 of the present invention was applied once a day for 60 consecutive days, and the pigmentation was lightened with an obvious improvement of the streaks on the left side (see Figure 31).

VII. Efficacy evaluation test

12220453_1 (GHMatters) P113315.AU

The efficacy evaluation test of the product of the present invention was commissioned to the

Dermatology Hospital of the Chinese Academy of Medical Sciences to evaluate the improvement of striae atrophicae by the product and the safety thereof. More details were as follows:

1. Goal and methodology of the study: by comparing the severity of striae atrophicae (including the quantitative analysis of the surface area of striae atrophicae) of a group of subjects before trial and 8 weeks after trial, the efficacy in striae atrophicae improvement by the product and the safety thereof were assessed. This clinical trial is designed as a single factor, before-and-after comparison of the same subject, and the product was distributed to the subjects with striae atrophicae who voluntarily participated and met the requirements, and clinical observation was carried out.

(1) Inclusion criteria: 1) healthy women aged from 18 to 45 years old; 2) apparent striae atrophicae on the abdomen, inner and outer thighs, knees, or other positions; 3) not entered in other clinical studies in recent three months; 4) consent to participate in this study and signing the informed consent;

(2) Exclusion criteria: 1) those who are allergic to any components of the known product, or who have allergic constitution; 2) those who have obvious skin defects at the striae atrophicae site that may affect the efficacy evaluation; 3) patients with serious heart disease history, liver and kidney diseases, hypertension; 4) patients with serious endocrine diseases, blood diseases, and neuropsychiatric disorders; 5) pregnant and lactating women; 6) subjects who have taken or topically applied retinoic acid-based drugs and glucocorticoids within 2 weeks before the start of the study; 7) patients who are not suitable for the trial for other reasons considered by the researchers.

(3) Exit and discontinuation criteria of subjects

During the study, all subjects who signed the informed consent and are qualified for the clinical study have the right to request unconditional withdrawal from the study at any time. The subjects is considered discontinuing from the study if they fail to complete the observation with regard to safety and effectiveness in the study, no matter when and for what reason the subjects withdraw from the clinical study, and those who have discontinued from the study are expulsion cases. The time and reason for discontinuation should be recorded in the case

12220453_1 (GHMatters) P113315.AU report.

Subjects selected for this study must withdraw from the study if any of the following conditions occur:

1) subjects have intolerable adverse events or need to change the treatment strategy leading to deviatioin from the clinical study program; 2) subjects voluntarily withdraw from the study;

3) serious violation of the research program and affecting the safety and effectiveness evaluation of the study; 4) failure in follow-up, out of contact with subjects; 5) pregnancy; 6) for the sake of safety and benefits, the researchers find the subjects not suitable to continue to participate in the study.

(2) Product studied:

The composition for removing striae atrophicae of Example 2 is composed of the compound essential oil and cream.

Product usage: the compound essential oil is applied to the striae atrophicae site, followed by application of the cream and proper pressing for facilitating absorption. Use at least once a day, twice a day is recommended.

The course of the study lasted for 8 weeks, and each subject was followed up 5 times (at weeks 0, 2, 4, 6, 8). The striae atrophicae to be tested were evaluated by the researchers before trial (week 0) and 2, 4, 6 and 8 weeks after trial. At weeks 0, 2, 4, 6, and 8, photographs were taken with high-definition digital camera (with the same light, distance and shooting angle), and quantitative analysis was done on the surface area of striae atrophicae. At weeks 0, 2, 4, 6, and 8, subjects performed self-assessment to assess the improvement of striae atrophicae.

(i) At week 0, the subjects were given instructions for the test, (ii) The subjects who participated in the test were selected according to the test requirements, and 35 qualified subjects were entered and signed the informed consent, (iii) After completing the selfassessment questionnaire, the qualified subjects were clinically observed, evaluated and photographed, (iv) User instructions were given to the subjects. The products were distributed to the subjects who had received the instructions. The subjects applied the test samples at home for 8 consecutive weeks. The subjects were reminded of the follow-ups at weeks 2, 4, 6 and 8 after continuous application according to the instructions of the test, (v) After 2 weeks, during the follow-up, the subjects were clinically observed, evaluated and photographed, and

12220453_1 (GHMatters) P113315.AU completed the self-assessment questionnaire, (vi) After 4 weeks, during the follow-up, the subjects were clinically observed, evaluated and photographed, and completed the selfassessmentquestionnaire. (vii) After 6 weeks, during the follow-up, the subjects were clinically observed, evaluated and photographed, and completed the self-assessment questionnaire, (viii) After 8 weeks, during the follow-up, the subjects were clinically observed, evaluated and photographed, and completed the self-assessment questionnaire. The surface area of the striae atrophicae was quantitatively analyzed with the Skin Surface Analyzer software.

The test samples were distributed to the subjects on the same day as the start of the test. After 8 weeks of continuous application, the samples were recorded and retrieved.

(5) Cautions for subjects (i) During the test, it is not allowed to perform any treatment to the site being tested that may influence the test, (ii) During the test, it is not allowed to apply other similar products and any other products that may influence the test.

(6) Effectiveness evaluation

1) Evaluation indicators

At the beginning of the study and during each follow-up, photographs were taken with a highdefinition digital camera (with the same light, distance and angle), and an SSA software was used to quantitatively measure the surface area of striae atrophicae, obtain objective quantitative parameters before and after application, and comprehensively evaluate the changes in striae atrophicae of the subjects before and after applying the product in combination with the assessment of the researchers and the subjects.

2) Efficacy indicators

At the end of the observation, the change in the surface area of striae atrophicae relative to the baseline in percentage was evaluated with the photographs of the subjects taken before and after the striae atrophicae test.

(7) Safety evaluation

The evaluation was carried out in accordance with the rating standards for skin reactions in the Cosmetic Safety Technical Specification (2015 Edition). Here, Table 7 shows the rating standards for skin reactions in a human use test.

Table 7

12220453_1 (GHMatters) P113315.AU

Skin reactions	Rating
No reaction	0
Slight erythema	1
Erythema, infiltration, papule	2
Erythema, edema, papule, blister	3
Erythema, edema, bleb	4

(8) Statistical analysis

Estimation of sample size: according to the requirements of the safety evaluation of a human use test in the Cosmetic Safety Technical Specification (2015 Edition), at least 30 volunteers were selected based on the inclusion criteria for the subjects. Considering the possibility of a 10-20% expulsion, the sample size was determined to be 35 cases.

A two-sided test was used for all the statistical tests, and unless otherwise specified, P < 0.05 will be considered that the differences as tested were statistically significant. Quantitative indexes describe the number, average value and standard deviation of the observed values. Classification indexes describe the number and percentage of each category. Since the quantitative analysis data of the striae atrophicae surface area did not fit to a normalized distribution, a rank-sum test was used in the effectiveness analysis to analyze the effect before and after applying the product. Adverse events and adverse reactions were recited in the safety analysis form, and the cause and explanation were listed. The safety of the product was evaluated according to the Cosmetic Safety Technical Specification (2015 Edition) issued bythe State Food and Drug Administration.

2. Results:

(1) Basic conditions of subjects

Totally 35 subjects who met the inclusion criteria participated in this trial voluntarily and signed the informed consent. These subjects were aged from a youngest 23 to an oldest 45 years old, with an average age of 29.875. Three of them failed to follow up on time due to business trips (that is, expulsion cases), and the remaining 32 completed 8 weeks of clinical observation.

(2) Effectiveness evaluation

The surface area of striae atrophicae was analyzed quantitatively by using an SSA analysis

12220453_1 (GHMatters) P113315.AU software (CK Co., Germany), and the improvement of striae atrophicae before and after applying the product was evaluated in combination with the clinical assessment from doctors and the self-assessment of the subjects. The results were as follows:

1) Clinical rating of striae atrophicae by researchers

Figure 32 is diagram of clinical ratings of striae atrophicae area, quantity and color at weeks 0, 2, 4, 6, and 8. Here, decrease percentage* percentage = (Wn-W0)/W0*100%.

Figure 33 is histogram of changes in clinical rating of striae atrophicae area at weeks 0, 2, 4, 6, and 8. Here, -3 indicates that the rating is lowered by three levels compared with the baseline value; -2 indicates that the rating is lowered by two levels compared with the baseline value; -1 indicates that the rating is lowered by one level compared with the baseline value; 0 indicates that the rating stays unchanged compared with the baseline value. Figure 34 is histogram of changes in clinical rating of striae atrophicae color at weeks 0, 2, 4, 6, and 8. Figure 35 is histogram of changes in clinical rating of striae atrophicae quantity at weeks 0, 2, 4, 6, and 8.

According to the rating changes in color, quantity and surface area ofthe striae atrophicae site, the researchers demonstrated an improvement in 72% ofthe subjects.

2) Quantitative analysis results ofthe striae atrophicae surface area before and after applying the product by SSA software (see Table 8 and Figure 36). Here, Table 8 is the statistical analysis results ofthe striae atrophicae surface area at weeks 0, 2,4, 6, and 8, and Figure 36 is a curve of changes in average striae atrophicae surface area at weeks 0, 2, 4, 6 and, 8.

Table 8

Time	N	Mean ± standard deviation	P value
wO	32	6.130313.14995
w2	32	5.594112.80466	0.417
w4	32	4.976912.33612	0.082
w6	32	4.530312.31075	0.016
w8	32	4.361612.46769	0.008

Table 8 shows p<0.05 at weeks 6, 8 after applying the product, showing a statistically significant difference in comparison to the case before the application of the product.

12220453_1 (GHMatters) P113315.AU

Figure 36 shows a tendency of decrease in the striae atrophicae surface area before and after applying the product, and statistics shows that 68.75% of the subjects had a reduction in surface area of more than 20% (see Annex 2 for the original data). This suggests that the product can improve striae atrophicae to some extent.

3) Evaluations of the product efficacy by the subjects are shown in Tables 9-14.

Table 9

	Changes in the number of striae atrophicae -W8
Increased	Slightly increased	Essentially unchanged	Decreased	Significantly decreased
Count	0	0	9	21	2
% in group	0	0	28.1	65.6	6.3

Table 10

	Changes in the area of striae atrophicae -W8
Increased	Slightly increased	Essentially unchanged	Decreased	Significantly decreased
Count	0	0	11	20	1
% in group	0	0	34.4	62.5	3.1

Table 11

	Changes in the color of striae atrophicae -W8
Darkened	Slightly darkened	Essentially unchanged	Lightened	Significantly lightened
Count	0	0	9	19	4
% in group	0	0	28.1	59.4	12.5

Table 12

	Changes in skin smoothness -W8
No improvement	Insignificant improvement	Moderate	Fair improvement	Significant improvement
Count	0	4	14	9	5
% in group	0	12.5	43.8	28.1	15.6

Table 13

12220453_1 (GHMatters) P113315.AU

	Changes in skin moisture -W8
No improvement	Insignificant improvement	Moderate	Fair improvement	Significant improvement
Count	0	2	16	9	5
% in group	0	6.3	50	28.1	15.6

Table 14

	Overall change of striae atrophicae -W8
No improvement	Insignificant improvement	Moderate	Fair improvement	Significant improvement
Count	0	4	18	7	3
% in group	0	12.5	56.3	21.9	9.4

Tables 9-14 show that 71.9% of the subjects found the number of striae atrophicae decreasec after applying the product. 65.6% of the subjects found the area of striae atrophicae decreased after applying the product. 71.9% of the subjects found the color of striae atrophicae was lightened after applying the product.

4) Photograph evaluation: photographs of some subjects before and after applying the product were compared, as shown in Figures 37-41 which illustrate the conditions of five users A-E before (left panel) and 8 weeks after applying the product (right panel) respectively.

The conditions of the three users A, B, C as presented in Figures 37-39 show a significant improvement of striae atrophicae. The conditions of the two users D, E as presented in Figures

40-41 show that striae atrophicae essentially disappeared. This suggests the product can indeed improve striae atrophicae.

(3) Safety evaluation

During the 8-week of the product application, the researchers did not see obvious adverse reactions such as erythema and papule on the skin of the subjects. The questionnaire results of the subjects during the follow-up at week 8 after using the product are shown in Table 15 below:

Table 15

	Skin irritation of the product -W8
Erythema	Desquamation	Itchiness	Twinging	Burning

12220453_1 (GHMatters) P113315.AU

Count	0	0	0	0	2
% in group	0	0	0	0	6.3

As seen from Table 15, only 2 subjects reported a local burning sensation, and 93.7% of the subjects had no adverse reaction, indicating that the product was well tolerated.

3. Results

To sum up, in view of the results from the effectiveness evaluation of the product, including the quantitative analysis of the striae atrophicae surface area, clinical ratings, and the selfassessment of the subjects, the product has an effect in improving striae atrophicae which has a statistically significant difference. During the 8-week observation, the vast majority of subjects (93.7%) did not report any skin adverse reactions, and the product was well tolerated.

Claims

1. A composition for removing striae atrophicae, wherein the composition is composed of a compound essential oil and a cream, the compound essential oil being composed of the following raw materials in mass percentage:

the cream being composed ofthe following raw materials in mass percentage:

base cream 98.5% to 99.5% essential oil composition 0.5% to 1.5%

and the essential oil composition being composed of the following raw materials in mass percentage:

lavender essential oil 15% to 35% Myrtus communis Linn essential oil 10% to 20% frankincense essential oil 10% to 15% Patchouli essential oil 10% to 15% vetivertone essential oil 8% to 15% carrot essential oil 8% to 15% palmarosa essential oil 8% to 15%

12220453_1 (GHMatters) P113315.AU

basil essential oil 2% to 5%.

2. The composition for removing striae atrophicae according to claim 1, where the compound essential oil is composed of the following raw material in mass percentage:

base essential oil 90% to 93% lavender essential oil 1.5% to 2% Myrtus communis Linn essential oil 0.8% to 1.3% frankincense essential oil 0.8% to 1.2% Patchouli essential oil 0.8% to 1.0% vetivertone essential oil 0.8% to 1.0% carrot seed essential oil 0.5% to 1.0% palmarosa essential oil 0.5% to 1.0% basil essential oil 0.4% to 0.5% C12-13 alkanol polyether-3 0.2% to 0.5% water 0.1% to 0.3% rosemary extract 0.1% to 0.2% Argireline 0.001%.

3. The composition for removing striae atrophicae according to claim 1 or 2, wherein the base essential oil is a mixture of any one of rosehip oil, grape seed oil, and macadamia oil together with jojoba oil.

4. The composition for removing striae atrophicae according to claim 1 or 2, wherein the base essential oil is a mixture of any one of rosehip oil, grape seed oil, and macadamia oil together with jojoba oil at a mass ratio of 1:1-2.

5. The composition for removing striae atrophicae according to claim 3, wherein the base essential oil is a mixture of any one of rosehip oil, grape seed oil, and macadamia oil together with jojoba oil at a mass ratio of 1:1-2.

12220453_1 (GHMatters) P113315.AU

6. The composition for removing striae atrophicae according to claim 1, wherein the base cream is composed of the following raw materials in mass percentage:

1,3-butanediol 3.5% to 4.5% caprylic/ capric triglycerides 3.5% to 4.5% glycerol 2.5% to 3.5% isononyl isononanoate 2.5% to 3.5% dioctyl carbonate 2.5% to 3.5% cetearyl glucoside 1.5% to 2.5% betaine 1.5% to 2.5% polydimethylsiloxane 1.5% to 2.5% jojoba oil 1.5% to 2.5% potassium cetyl phosphate 1.5% to 2.5% ethylhexylglycerol 0.3% to 0.6% hexamethylene glycol 0.3% to 0.6% hydroxyacetophenone 0.3% to 0.6% Carbomer 0.05% to 0.15% triethanolamine 0.05% to 0.15% Argireline 0.0005% to 0.0015% water add to 100%.

7. The composition for removing striae atrophicae according to claim 1 or 6, wherein the essential oil composition is composed of the following raw materials in mass percentage:

lavender essential oil 20% to 30% Myrtus communis Linn essential oil 12% to 19% frankincense essential oil 12% to 15% Patchouli essential oil 10% to 13% vetivertone essential oil 10% to 12% carrot essential oil 10% to 12% palmarosa essential oil 10% to 12% basil essential oil 3% to 5%.

12220453_1 (GHMatters) P113315.AU